Orphazyme CEO disappointed with failed ALS trial – pins hope on other disease area

Christophe Bourdon, Orphazyme's new CEO, is candid about the group's main candidate against ALS, arimoclomol, came out of its phase-3 trial with weak results.

Photo: Orphazyme / PR

It's disappointing that Orphazyme's main treatment candidate,against amyotrophic lateral sclerosis, arimoclomol, did not meet expectations in its phase III trial, Chief Executive Christophe Bourdon tells MedWatch after the news emerged Friday that the product has not been able to fulfill neither the primary nor secondary criteria in the crucial phase III trial.

"It's a setback. We were hoping to see a benefit of arimoclomol for ALS patients, and the data is very clear that there is no efficacy signal on the primary and secondary endpoints," says Bourdon, who emphasizes that no safety-related issues were reported in the study.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs